Business Wire

NORDTREAT

3.9.2024 06:51:33 CEST | Business Wire | Press release

Share
Nordtreat Has Appointed Outi Kallio as the New CEO

The Finnish technology company Nordtreat strengthens its growth by appointing Outi Kallio as the new CEO. Her era at Nordtreat will start from the turn of 2024/2025. Outi Kallio has a wealth of experience in commercial and industrial management, having held several key positions at Teknos Group.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240902513997/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Finnish technology company Nordtreat strengthens its growth by appointing Outi Kallio as the new CEO. (Photo: Business Wire)

Outi Kallio has an extensive background in sales, HR, and marketing. She also has a proven track record of leading international teams. Currently, she holds the position of Global Commercial Director at Teknos Group.

"As Nordtreat continues to grow and evolve, we are thrilled to welcome Outi Kallio as our new CEO. Her diverse experience and proven leadership skills make her the ideal candidate to lead Nordtreat into its next chapter. We believe that Outi Kallio’s strategic vision and operational expertise will drive our company forward and enhance shareholder value," says Leif Frilund, Chairman of the Board of Nordtreat.

"With over a decade of experience in the coatings industry, I have seen a growing shift towards sustainable solutions, driven by increasing customer expectations. Nordtreat's commitment to bio-based technologies and its strong ethos of responsibility provides a solid foundation for scaling Finnish sustainability expertise into an international growth story. I am excited to join this team of top professionals and look forward to contributing to our shared success," Outi Kallio says.

As Nordtreat’s CEO, Outi Kallio will succeed Aki Borgentorp, who has led the company for ten years. These years have included the development of the first truly bio-based flame retardant for wood-based materials and the growth of a worldwide market presence.

"Over the past decade, Nordtreat has built a scalable platform for the development and production of bio-based flame retardants for wood-based materials. I am convinced that under Outi Kallio’s leadership, Nordtreat will continue to innovate and expand its presence in the market and make a significant impact in the construction materials industry," says Aki Borgentorp.

"On behalf of the Nordtreat board, I’d like to express our sincere gratitude to Aki Borgentorp for his remarkable achievement in building Nordtreat from scratch into a leading provider of new sustainable flame-retardant solutions. We wish Aki the best of success in his future endeavours," Leif Frilund says.

Nordtreat has also welcomed Dr Thomas Kostka, the Head of Corporate Venturing at Altana AG, to join the board of directors starting in August 2024. Additionally, Nordtreat has appointed Sakari Saarela, a partner in the UB FIGG Fund, as a board observer. Sampsa Auvinen, who has been on Nordtreat's board since 2022, will continue as UB FIGG's representative on the board. Sampsa Auvinen is also the Chairman of the Advisory Board of UB FIGG. Altana Group, the global leader in true specialty chemicals, and the Finnish sustainability fund UB Forest Industry Green Growth Fund (UB FIGG), a growth private equity fund investing in sustainable and resource-efficient forest and bio-based industries, announced an investment in Nordtreat in June 2024.

"We are happy to welcome Thomas Kostka to the board of directors at Nordtreat. He brings us a deep understanding of the industry and strategic insights that will be invaluable as we continue to grow," says Leif Frilund.

Image folder

Nordtreat is a Finnish technology company founded in 2015, specializing in the development and production of environmentally friendly, high-performance flame retardants. Utilizing bio-based raw materials, Nordtreat's products comply with the latest fire protection regulations and have been used to protect over 2000 buildings worldwide. The company's flagship technology, NORFLAM®, is designed to provide superior fire protection while maintaining environmental sustainability. Nordtreat's innovative solutions are aimed at meeting the growing global demand for safer, more sustainable construction materials. www.nordtreat.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240902513997/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye